Boston Scientific Corporation (BSX) is a Medical - Devices company in the Healthcare sector, currently trading at $63.82. It has a SharesGrow Score of 80/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BSX = $103.80 (+62.6% from the current price, the stock appears undervalued). Analyst consensus target is BSX = $108 (+69.8% upside).
Valuation: BSX trades at a trailing Price-to-Earnings (P/E) of 31.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.45.
Financials: revenue is $20.1B, +16.6%/yr average growth. Net income is $2.9B, growing at +66.8%/yr. Net profit margin is 14.4% (healthy). Gross margin is 69% (+0.6 pp trend).
Balance sheet: total debt is $12.4B against $24.2B equity (Debt-to-Equity (D/E) ratio 0.51, moderate). Current ratio is 1.62 (strong liquidity). Debt-to-assets is 28.4%. Total assets: $43.7B.
Analyst outlook: 40 / 43 analysts rate BSX as buy (93%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 51/100 (Partial), Growth 90/100 (Pass), Past 100/100 (Pass), Health 83/100 (Pass), Moat 80/100 (Pass), Future 100/100 (Pass), Income 55/100 (Partial).
